sponsored
PatientsVille.com Logo

PatientsVille

Votrient Medical Research Studies

Up-to-date List of Votrient Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Votrient Medical Research Studies

Rank Status Study
1 Recruiting Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Condition: Thyroid Carcinoma
Interventions: Drug: Continuous pazopanib (Arm A);   Drug: Intermittent pazopanib (Arm B)
Outcome Measures: Time to treatment failure (TTF);   Objective Response Rate (ORR);   Disease Control Rate (DCR);   Progression-Free Survival (PFS);   Best response rate;   Duration of response;   Overall Survival (OS);   Disease Control Rate (SDR);   Safety profile of pazopanib;   Quality of Life (QoL)
2 Not yet recruiting PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conditions: Ovarian Neoplasms;   Neoplasms, Ovarian;   Ovarian Cancer
Interventions: Drug: Pazopanib;   Drug: Fosbretabulin
Outcome Measures: Phase Ib: Dose Limiting Toxicities of Dose of Pazopanib and Fosbretabulin;   Phase II: Progressive disease;   Phase I: Biomarker changes on a cohort-by cohort basis;   Phase Ib and Phase II: Safety and Toxicity profile of Pazopanib and Fosbretabulin in combination;   Phase II: Biomarker signature for Progression Free Survival;   Phase II: Response rates by RECIST and GCIG CA-125 criteria;   Phase II: Biomarker response in combination arm
3 Not yet recruiting Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Condition: Solid Tumours
Intervention: Drug: Pazopanib GW786034
Outcome Measures: The investigator assessed objective response rate (ORR) in subjects' with tumors of primary interest;   The investigator assessed ORR for the tumor types of secondary interest.;   Toxicities of oral pazopanib;   Progression free survival (PFS) as assessed by the Investigator in subjects with relapsed or refractory solid tumors;   The time to progression (TTP) in subjects with relapsed or refractory solid tumors;   The therapeutic activity (a confirmed complete or partial response or stable disease for at least 4 cycles) per stratum;   The relationship between tumor response and angiogenic cytokines.;   VEGF and KDR genotype/phenotype relationships in subjects with cancer treated with pazopanib.;   Pazopanib pharmacokinetic/pharmacodynamic relationships with biomarkers and clinical outcomes
4 Not yet recruiting Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib + Pazopanib;   Drug: Pazopanib + Sorafenib
Outcome Measures: To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.;   Time from randomization to progression during second-line therapy (total TTP);   Time to first-line treatment failure (progression, death, discontinuation due to toxicity) descriptively in each arm;   PFS in first-line and second-line treatment, descriptively;   Overall survival, descriptively (data cut-off same as for primary endpoint);   Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD according to RECIST criteria);   Health-related Quality of Life (FACIT-F, FKSI-10);   Biomarker programme;   Number of Adverse Events
5 Recruiting Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib+Pazopanib;   Drug: Pazopanib+Sorafenib
Outcome Measures: To evaluate if progression-free survival from randomization to progression or death during second-line therapy (Total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.;   Time from randomization to progression during second-line therapy (total TTP);   Time to first-line treatment failure (progression, death, discontinuation due to toxicity) descriptively in each arm;   PFS in first-line and second-line treatment, descriptively;   Overall survival, descriptively (data cut-off same as for primary endpoint;   Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD according to RECIST criteria);   Health-related Quality of Life (FACIT-F, FKSI-10);   Biomarker programme;   Safety and tolerability
6 Recruiting Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Crizotinib (Xalkori);   Drug: Pazopanib;   Drug: Pemetrexed
Outcome Measure: Maximum Tolerated Dose (MTD)
7 Unknown  Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Condition: Acute Myeloid Leukemia
Intervention: Drug: Pazopanib
Outcome Measures: Cumulative response rate (CR, CRp, CRi, PR) within up to one year of pazopanib treatment;   Reduction of BM microvessel density on day 28;   Safety and Tolerability (Rate of adverse events);   Cumulative incidence and degree of inhibition of target receptor phosphorylation (PDGFR, VEGFR, and c-KIT) and correlation with clinical response;   Reduction of BM microvessel density on day 14;   Relapse-free survival in relationship to historical control patients, Overall survival in relationship to historical control patients, Duration of response
8 Recruiting A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Condition: Advanced Soft Tissue Sarcoma
Intervention: Drug: TRC105 and Pazopanib
Outcome Measures: Determine Maximum Tolerated Dose of TRC105 in Combination with Pazopanib;   Characterize TRC105 pharmacokinetic Concentrations when given with pazopanib
9 Recruiting Pazopanib, Docetaxel, Prednisone Prostate
Condition: Prostate Cancer
Interventions: Drug: Pazopanib;   Drug: Docetaxel;   Drug: Prednisone;   Drug: Pegfilgrastim
Outcome Measures: Number and Percent of Participants with Adverse Events as a Measure of Safety and Tolerability; Number and Percent of participants who have disease progression;   Establish the maximum tolerated dose;   Measurement of pazopanib and docetaxel drug levels in participants.;   Relationship between genetic variants and drug levels (Cmax, Tmax, AUC, CL, Vd).;   Establish the optimal dosing schedule
10 Recruiting Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
Condition: Sarcoma, Soft-tissue
Intervention: Drug: pazopanib
Outcome Measures: Metabolic response rate;   Percentage of tumor tissue with regressive alterations upon resection ("Histopathological Response");   Decrease in tumor size in MRI according to RECIST 1.1 criteria;   Change of FDG influx as well as of transport rates k1-k4 and distribution volume VB and fractal dimension in dynamic PET-CT ("Dynamic PET-CT Response");   Number of days for which planned resection is delayed after treatment;   Number of patients in which adverse events occur during treatment;   Disease-free survival;   Local recurrence-free survival;   Distant recurrence-free survival;   Overall survival;   Decrease in vascularisation in MRI according to adapted Choi Criteria;   Decrease in MRI apparent diffusion coefficient (ADC) values
11 Recruiting Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
Conditions: Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Stage IIA Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: placebo;   Procedure: therapeutic conventional surgery;   Radiation: external beam radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: Absolute values and changes in maximum SUV of tumors measured by FDG-PET pre- and post receipt of pazopanib versus placebo, and post receipt of 2 courses of preoperative chemotherapy;   Tumor response by RECIST criteria;   Correlation of pazopanib hydrochloride trough concentration with the change in SUV from FDG PET and change in RECIST measurements on MRIs;   Safety profile of sequential treatment with pazopanib and pre-operative chemotherapy with doxorubicin and ifosfamide;   Pathologic response at the time of surgery as measured by % tumor viability;   Progression free survival;   Overall survival;   Change in plasma and tumor angiogenic biomarker levels pre- and post neoadjuvant therapy
12 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
Outcome Measures: Rate of poor risk patients as defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria who are free of disease progression at 6 months after start of first line treatment with pazopanib.;   Number, characteristics and severity of Adverse Events;   Progression free survival of patients treated with pazopanib;   Overall response rate and duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1;   Relation between biomarkers and clinical outcome (response, stable disease, progression of disease);   Overall survival of poor risk patients treated with pazopanib.
13 Recruiting Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: Biologically optimal dose (BOD) defined as the dose level and diet in combination that induces no toxicity requiring dose modification per protocol and achieves a satisfactory pazopanib trough concentration (Cmin greater than 30 μg/mL);   Time until any treatment-related toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Time to progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;   Time to treatment failure;   Steady state trough pazopanib hydrochloride levels as determined by cytochrome P450 or other polymorphisms;   Pazopanib hydrochloride levels with observed pazopanib hydrochloride toxicities
14 Not yet recruiting Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
Conditions: Germ Cell Tumors;   Measurable Disease;   Relapse or Progression After 2 or 3 Chemotherapy Regimens.;   Relapse or Progression After High-dose Chemotherapy.
Intervention: Drug: Pazopanib
Outcome Measures: Progression Free Survival;   Safety and tolerability of pazopanib according to the Common Terminology Criteria for Adverse Events version 4.03;   Response Rate;   Overall survival (OS)
15 Recruiting Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
Condition: Metastatic Cancer (Different Solid Tumour Types)
Intervention: Drug: Pazopanib
Outcome Measures: Dose limiting toxicity (DLT) incidence (according DLT definition) during the first treatment cycle with pazopanib (28 days);   Safety and tolerability assessments using the descriptions and grading scales found in the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0 NCI;   Measure of Pazopanib plasma concentration during treatment period (objective : assessment of pharmacokinetics of Pazopanib in this population);   Geriatric criteria measured by comprehensive geriatric assessment which evaluate medical, functional and psychosocial aspects of elderly patients;   Rate of objective response according to RECIST criteria
16 Not yet recruiting Pazopanib, Food, Tolerability
Condition: Cancer
Interventions: Drug: pazopanib;   Other: continental breakfast
Outcome Measures: Area under the plasma concentration versus time curve (AUC) of pazopanib;   number of side effects;   questionnaire
17 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
Outcome Measures: Part 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs );   Part 1: To determine the dose limiting toxicity (DLT) and maximum tolerated regimen (MTR);   Part 1: Number of subjects with permanent discontinuation of treatment, dose reductions, interruptions, or delays;   Part 1: Change from baseline in laboratory parameters;   Part 1: Change from baseline in vital signs;   Part 1: Change from baseline in cardiac parameters;   Part 1: Incidence and titer of anti MK 3475 antibodies;   Part 2: Progression-free survival (PFS);   Part 1: Dose escalation cohorts: pazopanib plasma concentrations and serum MK 3475 concentrations.;   Part 1: Pharmacokinetic (PK) parameters in Expansion cohort;   Part 1 and Part 2: Overall response rate (ORR);   Part 1 and Part 2: Clinical benefit rate;   Part 1 and Part 2: Time to response;   Part 1 and Part 2: Duration of response;   Part 2: PFS by modified RECIST;   Part 1 and Part 2: Progression-free survival rate at 18 months (PFSR18);   Part 2: Overall survival (OS) at 18 months;   Part 2: Overall survival (OS);   Part 2: Incidence and severity of AEs and SAEs;   Part 2: Number of subjects with permanent discontinuation of treatment, dose reductions, interruptions, or delays;   Part 2: Change from baseline in laboratory parameters;   Part 2: Change from baseline in vital signs;   Part 2: Change from baseline in cardiac parameters;   Part 2: Incidence and titer of anti MK 3475 antibodies in patients treated with pazopanib + MK 3475 and single-agent MK 3475;   Part 2: PK parameters in randomized phase
18 Recruiting Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Hemangioendothelioma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Hemangiopericytoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride;   Drug: pazopanib hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis
Outcome Measures: Progression-free survival (PFS);   PFS (for a sub-group of patients treated with single-agent pazopanib hydrochloride following administration of gemcitabine hydrochloride in the cross-over portion of this study);   Response rate (RR);   Best overall response rate (ORR);   Overall survival (OS);   Adverse events and serious adverse events, defined using the Common Terminology Criteria for Adverse Events (CTCAE) v 4.0.
19 Recruiting Rotating Pazopanib and Everolimus to Avoid Resistance
Condition: Clear Cell Renal Carcinoma
Interventions: Drug: Pazopanib;   Drug: Everolimus
Outcome Measures: Progression free survival;   Time to second progression;   Change in Quality of life assessed by the FKSI-DRS and EORTC QLQ-C30 questionnaires compared to baseline;   Toxicity reported as number/percentage of patients with adverse events;   Overall survival
20 Recruiting Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Condition: Ovarian Cancer
Intervention: Drug: pazopanib in combination with weekly topotecan
Outcome Measures: Phase I: Assessment of dose-limiting toxicity in order to determine the maximum tolerated dose (MTD) of pazopanib in combination with weekly topotecan;   • Phase II: Progression-free survival according to RECIST criteria;   • Overall survival;   • Response rate (CR, PR) according to RECIST criteria;   • Clinical benefit rate (CR, PR, SD);   • Duration of response;   • Time to progression (TTP);   • Evaluation of CA-125 tumour response;   Safety and tolerability of pazopanib in combination with weekly topotecan;   • Quality of life as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire

These studies may lead to new treatments and are adding insight into Votrient etiology and treatment.

A major focus of Votrient research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Votrient